Ambio Life Sciences’ Post

Glimpsing the future of #siRNA delivery strategies and the broader therapeutic application of #oligonucleotides #RNAitherapeutics pose challenges to drug developers due to their poor physiochemical properties. In this viewpoint #article, Naim Nazef (Head of Oligonucleotide Chemistry and Development Platforms, Takeda) speaks about the challenges and advances in #siRNAdelivery, and the burgeoning promise of #oligonucleotidetherapeutics for targeting a wide array of diseases. Read at your convenience below: https://buff.ly/3Y47g2o

Photosensitivity characterizes porphyria cutanea tarda,with differentiation from other porphyrias identified by deficiency of uroporphyrinogen Ill decarboxylase enzyme; enzymatic activity < 20% prior to observation of clinical symptoms.(NIH 5/4/2021)

🔴 The anti-IBD effects of Plants Unveiled! 🔴 ⚜ Regulation of TLRs by #Plants: From epigenetic to post-translational modification (#PTM)  ✔ Interested in how #plant-derived compounds can help treat inflammatory bowel disease (#IBD) by modulating toll-like receptors (TLRs)? ✔ Check out our recently published comprehensive #review article that summarizes the current evidence and future direction ⚜Phytomedicine, IF: 7.9, CS: 10.4 🔻 Download the article here: https://lnkd.in/dxc2pjBm ⏰ 30 min Roodabeh Bahramsoltani Amir Hossein Abdolghaffari

Cystic fibrosis: a genetic disorder impacting lungs and digestion. Thick mucus leads to infections, breathing difficulties, and digestive issues. Though there's no cure, Trikafta is an extremely effective medication against CF and can add over double the lifespan to someone affected. What an incredible feat! 💪 #bigpharma #pharma #prescriptionmedicine #affordablehealthcare #affordablehealthinsurance #affordablemedicine #prescriptioncosts #affordableprescriptions #genericmedicine #americanhealthcare #dirx #dirxhealth #cysticfibrosis #fightcf #trikafta

Photosensitivity characterizes porphyria cutanea tarda,with differentiation from other porphyrias identified by deficiency of uroporphyrinogen Ill decarboxylase enzyme; enzymatic activity < 20% prior to observation of clinical symptoms.(NIH 5/4/2021)

Photosensitivity characterizes porphyria cutanea tarda,with differentiation from other porphyrias identified by deficiency of uroporphyrinogen III decarboxylase enzyme; enzymatic activity < 20% prior to observation of clinical symptoms.(NIH 5/4/2021)

Ozempic and Wegovy have been in the news as the first highly effective weight loss drugs on the market. However, a noted side effect—nausea—can make it difficult for patients to adhere to proper use. Luckily, OBESITYsym is now available to help researchers develop effective treatments with patients with obesity while avoiding nausea as a side effect. In this webinar, you’ll learn how this new QSP model can… -Predict optimal dosing strategies -Predict weight loss -Predict nausea based on specific compound characteristics - Compare novel compound performance against semaglutide, tirzepatide and liraglutide Register now: https://lnkd.in/gn-G7xdP

Join Celeste Vallejo, Zack Kenz, Steve Chang, and myself for a webinar on March 6 where we will introduce our newest QSP model, OBESITYsym. I am really excited to share the progress our Simulations Plus QSP team has made in developing OBESITYsym. In some ways, this is the culmination of some 30 years in and out of this field, ranging back to my days as a graduate student in the Nutrition department at UC Berkeley. Progress with obesity treatments has come in fits and starts until quite recently. The impact that effective, sustained weight loss can have on global public health is greater than I ever could have imagined back in my days in graduate school. The quality of the work that went into this modeling effort is top notch, and the potential impact it could have on accelerating the development of effective and tolerable treatments for patients is tremendously high. We expect OBESITYsym to contribute to the next wave of obesity drugs, improving efficacy, tolerability, and quality of life. https://lnkd.in/gCNWjaxd

Pharmacovigilance is an ongoing process at the heart of our daily clinical practice. In this case report, we present the first ever-known case of #Takotsubo cardiomyopathy in a postmenopausal female patient with metastatic #BreastCancer, without prior exposure to cardiotoxic antineoplastic agents, in the context of combinational #EndocrineTherapy with Palbociclib plus Letrozole. Nick (Nikos) Syrigos Elias Kotteas, MD, PhD https://lnkd.in/dgdC259s

Network meta-analysis (15 RCTs involving 1832 patients) of pharmacological treatments for #autoimmune disease-associated #ILD: 🔹Cyclophosphamide, #rituximab, #tocilizumab, nintedanib and pirfenidone are effective in the treatment of autoimmune disease-associated ILD 🔹Current evidence does not support the use of #bosentan and pomadomide in autoimmune disease-associated ILD 🔹#Riociguat also has good therapeutic potential, but it still needs to be proven in larger RCTs.  🔹#Nintedanib+mycophenolate mofetil is a successful combination therapy with great efficacy and safety, and its superiority needs to be demonstrated in future studies.  🔹Tolerance of nintedanib and #pirfenidone is a concern, as their common adverse events are gastrointestinal disorders. 🔗https://lnkd.in/dxuBTcNR